The efficacy of sofosbuvir-based DAAs treatment on chronic hepatitis C patients with pan-genotypic hepatitis C viral infection

Abstract

Abstract: Objective To evaluate the efficacy of sofosbuvir-based direct-acting antiviral agents (DAA) treatment on chronic hepatitis C patients with pan-genotypic hepatitis C viral infection. Methods A total of 134 Patients diagnosed with chronic hepatitis C in the Liver Diseases Branch of Fourth Affiliated Hospital of Xinjiang Medical University from July 2017 to January 2020 were collected and retrospectively analyzed. These patients received sofosbuvir-based DAAs and completed the recommended treatment course. They had been tested with highly sensitive hepatitis C RNA quantification method during the treatment to observe the sustained virological response (SVR) rate of antiviral treatment. Results Within the 134 patients, 72 were males and 62 were females; 95 patients were <60 years old, 39 patients were ≥60 years old; 121 patients were Han nationality, 13 patients were ethnic minorities; 118 were treatment naïve patients, 16 patients had previous treatment-experience; 59 patients were cirrhotic and 75 were non-cirrhotic; For the infected HCV genotype (GT): 53 patients were GT 1b, 57 patients were GT 2a, 10 patients were GT 3a, 12 patients were GT 3b, 1 patient was of GT 6, and 1 patient was mixed GTs 1b and 2a. For GT1b, 23 patients were treated with sofosbuvir/velpatasvir,16 patients were treated with sofosbuvir plus ribavirin, 11 patients were treated with ledipasvir/sofosbuvir and 3 patients were treated with sofosbuvir plus daclatasvir for 12 weeks. For GT 2a, 32 patients were treated with sofosbuvir/velpatasvir, 5 patients were treated with sofosbuvir/velpatasvir plus ribavirin and 20 patients were treated with sofosbuvir plus ribavirin for 12 weeks. For GT 3, 16 patients were treated with sofosbuvir/velpatasvir for 12 weeks; 6 patients were treated with sofosbuvir plus ribavirins for 12-24 weeks. For GT 6: 1 patient was treated with sofosbuvir plus ribavirin tablets for 12 weeks. For mixed GTs (1b, 2a): 1 patient was treated with sofosbuvir/velpatasvir for 12 weeks. Sofosbuvir-based DAAs treatment of all patients with chronic hepatitis C reached SVR. Conclusion The Sofosbuvir-based DAAs treatment has a high overall SVR and well tolerance in chronic hepatitis C patients with pan-genotypic HCV infection.

Key words: chronic hepatitis C, hepatitis C viral infection, pan-genotype, sofosbuvir, sustained virological response rate

GUO Feng, DOU Jing, XU Qiang, WANG Xiao-bo, MA Yan, YUE Yong-hong, Huxibaiheti, WANG Zhuan-guo, WANG Hong-feng, WANG Xiao-zhong. The efficacy of sofosbuvir-based DAAs treatment on chronic hepatitis C patients with pan-genotypic hepatitis C viral infection[J]. Chinese Hepatolgy, 2021, 26(11): 1224-1227.

References

[1] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2019更新版).临床肝胆病杂志,2019,35:2670-2686.
[2] Schiff ER,Sorrell MF,Maddrey EC,et al.Schiff's Diseases of the liver,Eleventh Edition.Wang FS.Beijing:Peking University Medical Press,2015:551.
[3] Bourlière M,Oules V,Ansaldi C,et al.Sofosbuvir as backbone of interferon free treatments.Dig Liver Dis,2014;46:S212–S220.
[4] Ghany MG,Morgan TR,AASLD-IDSA Hepatitis C Guidance Panel.Hepatitis C guidance 2019 update:American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for testing, managing,and treating hepatitis C virus infection.Hepatology,2020,71:686-721.
[5] European Association for the Study of the Liver.EASL Recommendations on Treatment of Hepatitis C 2018.J Hepatol,2018,69:461-511.
[6] Wei L,Xie Q,Huang Y,et al.Safety and efficacy of Sofosbuvir/Velpatasvir in genotype 1-6 HCV-infected patients in China: results from a phase 3 clinical trial.San Francisco:AASLD,2018.
[7] Gayam V,Mandal AK,Khalid M,et al. Sofosbuvir based regimens in the treatment of chronic hepatitis C with compensated liver cirrhosis in community care setting. Int J Hepatol,2018,2018:4136253.
[8] Hu C,Yuan G,Liu J,et al.Sofosbuvir-based therapies for patients with hepatitis C virus infection:real-world experience in China.Can J Gastroenterol Hepatol,2018,2018:3908767.
[9] Wei L,Xie Q,Hou JL,et al.Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China. J Gastroenterol Hepatol,2018,33:1168-1176.
[10] Abid K,Pazienza V,de Gottardi A,et al.An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation.J Hepatol,2005,42:744–751.
[11] Berden FA,Aaldering BR,Groenewoud H,et al.Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection:a systematic review and network meta-analysis.Clin Gastroenterol Hepatol,2017,15:349-359.
[12] Buggisch P,Wursthorn K,Stoehr A,et al.Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.PLoS One,2019,14:e0214795.
[13] Seo K, Kim SK, Kim SR, et al.Comparison of sofosbuvir plus ribavirin treatment with pegylated interferon plus ribavirin treatment for chronic hepatitis C genotype 2.Dig Dis,2017,35:541-547.
[14] Huang R,Rao H,Xie Q,et al.Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.J Med Virol,2019,91:1313-1318.